Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Michael Shannon

Endocrinology, Diabetes & Metabolism Lacey, WA Medical Doctor

NPI 1366551285 CMS profile 243329

2555 Marvin Rd Ne, Pmg Sw Wa Olympia Endocrine, Lacey, WA 98516

Open in the dashboard

General payments

$698,092

831 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Michael Shannon of Lacey, WA is reported in the CMS Open Payments database as having received $698,092 across 831 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Endocrinology, Diabetes & Metabolism profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $116,983 125
2024 General $49,560 54
2023 General $79,603 95
2022 General $104,306 116
2021 General $94,498 109
2020 General $39,457 24
2019 General $213,684 308

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Michael Shannon
  • Endocrinology, Diabetes & Metabolism median
  • Middle half of Endocrinology, Diabetes & Metabolism
  • National median

In program year 2025, general payments to Michael Shannon were reported at $116,983. Among 5,868 Endocrinology, Diabetes & Metabolism profiles paid that year, the median was $507 and the middle half received between $135 and $1,838.

Show as a table
Year Michael Shannon Endocrinology, Diabetes & Metabolism median Middle half National median
2019 $213,684 $494 $123–$2,253 $163
2020 $39,457 $335 $85–$1,841 $114
2021 $94,498 $398 $88–$1,981 $132
2022 $104,306 $364 $88–$1,568 $149
2023 $79,603 $420 $113–$1,614 $160
2024 $49,560 $440 $121–$1,646 $164
2025 $116,983 $507 $135–$1,838 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Novo Nordisk Inc $415,575 411 payments
  2. Bayer HealthCare Pharmaceuticals Inc. $159,173 200 payments
  3. Lilly USA, LLC $74,346 143 payments
  4. Boehringer Ingelheim Pharmaceuticals, Inc. $44,703 63 payments
  5. Eli Lilly and Company $2,027 2 payments
  6. Shire North American Group Inc $1,240 1 payment
  7. AstraZeneca Pharmaceuticals LP $255 4 payments
  8. Amgen Inc. $233 2 payments
  9. Genentech USA, Inc. $150 1 payment
  10. Corcept Therapeutics $140 2 payments
  11. Other $250 2 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $509,596 258 payments
  2. Consulting Fee $96,383 24 payments
  3. Travel and Lodging $73,538 284 payments
  4. Food and Beverage $18,542 264 payments
  5. Education $32 1 payment
Products named General payments · program years 2019–2025
  1. Ozempic $168,204 165 payments
  2. RYBELSUS $134,567 138 payments
  3. Kerendia $127,272 162 payments
  4. JARDIANCE Diabetes $44,495 61 payments
  5. TRULICITY $41,200 85 payments
  6. JARDIANCE Diabetes $33,220 51 payments
  7. Tresiba Diabetes $11,646 5 payments
  8. Non-Covered $2,404 3 payments
  9. Tresiba Diabetes $1,314 4 payments
  10. NATPARA (PARATHYROID HORMONE) $1,240 1 payment
  11. Other $1,328 17 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

831 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Endocrinology, Diabetes & Metabolism in Washington

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record